Clinical Trials Logo

PD-1 clinical trials

View clinical trials related to PD-1.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05741021 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label, and multicenter phase Ⅱ study designed to evaluate the efficacy and safety of rulonilimab combined with chemotherapy in patients with advanced or metastatic non-small cell lung Cancer (NSCLC). Two cohorts were designed in this study: cohort 1 (non-squamous NSCLC) and cohort 2 (squamous NSCLC). About 84 patients with advanced or metastatic NSCLC plan to be enrolled in about 20 study sites of the study.

NCT ID: NCT04814069 Not yet recruiting - Clinical trials for Head and Neck Cancer

A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma:The POTENTIAL Study

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

To investigate whether concurrent Tislelizumab with postoperative chemoradiotherapy would have survival benefit in high Risk HNSCC Patients.

NCT ID: NCT04690036 Not yet recruiting - Transplant Clinical Trials

PD-1 Antibody for Reactive EBV After BMT

Start date: July 1, 2021
Phase: Early Phase 1
Study type: Interventional

PD-1 antibody for reactivation of EBV after transplantation in patients with CAEBV/EBV-HLH

NCT ID: NCT04284202 Not yet recruiting - NSCLC Stage IV Clinical Trials

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

Start date: March 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evalute the efficacy and safety of PD-1 antibody combined with Dasatinib as third-line therapy for NSCLC patients with ARID1A mutation until disease progression or intolerable toxicity or patients withdrawal of consent. The target sample size is 30+individuals. The primary endpoint of this study is PFS、ORR、OS and the secondary endpoint is toxicity.

NCT ID: NCT04061928 Not yet recruiting - Clinical trials for Gastroesophageal Junction Cancer

Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ

Start date: August 26, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to investigate the safety and efficacy of radiotherapy combined with Toripalimab (PD-1 inhibitor) in the treatment of locally advanced adenocarcinoma of the gastroesophageal junction.